156 related articles for article (PubMed ID: 17347872)
1. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experiments.
Hanauske AR; Oberschmidt O; Hanauske-Abel H; Lahn MM; Eismann U
Invest New Drugs; 2007 Jun; 25(3):205-10. PubMed ID: 17347872
[TBL] [Abstract][Full Text] [Related]
2. Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hanauske-Abel HM; Blatter J; Ma D; Chen V; Lahn M
Invest New Drugs; 2008 Jun; 26(3):215-22. PubMed ID: 18000644
[TBL] [Abstract][Full Text] [Related]
3. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
4. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
5. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Lee SH; Chen T; Zhou J; Hofmann J; Bepler G
Clin Lung Cancer; 2010 May; 11(3):169-75. PubMed ID: 20439192
[TBL] [Abstract][Full Text] [Related]
7. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C beta in malignant pleural mesothelioma.
Faoro L; Loganathan S; Westerhoff M; Modi R; Husain AN; Tretiakova M; Seiwert T; Kindler HL; Vokes EE; Salgia R
Anticancer Drugs; 2008 Oct; 19(9):841-8. PubMed ID: 18765998
[TBL] [Abstract][Full Text] [Related]
9. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
10. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
16. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.
Gray JE; Altiok S; Alexandrow MG; Walsh FW; Chen J; Schell MJ; Tai DF; Bepler G
Cancer; 2013 Mar; 119(5):1023-32. PubMed ID: 23065656
[TBL] [Abstract][Full Text] [Related]
18. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Willey CD; Xiao D; Tu T; Kim KW; Moretti L; Niermann KJ; Tawtawy MN; Quarles CC; Lu B
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1518-26. PubMed ID: 19906497
[TBL] [Abstract][Full Text] [Related]
19. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
20. The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
Cadron I; Van Gorp T; Mihalyi A; Luyten C; Drijkoningen K; Amant F; Leunen K; Vergote I
Gynecol Oncol; 2010 Jul; 118(1):64-8. PubMed ID: 20439112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
